Harvard Bioscience, Inc.
HBIO
$6.04
$0.030.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.78M | -56.70M | -53.84M | -57.41M | -58.05M |
| Total Depreciation and Amortization | 5.64M | 5.95M | 6.36M | 6.85M | 7.03M |
| Total Amortization of Deferred Charges | 1.64M | 1.32M | 796.00K | 528.00K | 388.00K |
| Total Other Non-Cash Items | 2.63M | 50.49M | 49.24M | 50.42M | 51.79M |
| Change in Net Operating Assets | 2.96M | 5.67M | 6.00M | 6.24M | 1.87M |
| Cash from Operations | 3.08M | 6.73M | 8.55M | 6.62M | 3.02M |
| Capital Expenditure | -1.17M | -1.26M | -1.11M | -1.78M | -2.51M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -629.00K | -605.00K | -620.00K | -710.00K | 710.00K |
| Cash from Investing | -1.80M | -1.86M | -1.73M | -2.49M | -1.80M |
| Total Debt Issued | 40.00M | 40.00M | 0.00 | 3.25M | 6.30M |
| Total Debt Repaid | -36.35M | -37.35M | -4.00M | -4.00M | -6.05M |
| Issuance of Common Stock | 197.00K | 47.00K | 207.00K | 222.00K | 365.00K |
| Repurchase of Common Stock | -111.00K | -156.00K | -617.00K | -593.00K | -605.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.83M | -3.83M | -687.00K | -594.00K | -290.00K |
| Cash from Financing | -96.00K | -1.29M | -5.10M | -1.72M | -280.00K |
| Foreign Exchange rate Adjustments | 367.00K | 931.00K | 525.00K | 978.00K | 350.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.55M | 4.51M | 2.25M | 3.39M | 1.29M |